{"product_id":"collegiumpharma-marketing-mix","title":"Collegium Pharmaceutical Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReady-Made Marketing Analysis, Ready to Use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Collegium Pharmaceutical’s product portfolio, pricing architecture, distribution channels, and promotional tactics combine to drive market impact in a concise 4P’s snapshot. This preview highlights key trends—get the full, editable Marketing Mix Analysis for detailed data, strategic recommendations, and ready-to-use slides to save hours and win decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAbuse-deterrent pain formulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollegium centers its portfolio on abuse-deterrent opioid technologies—notably Xtampza ER, which received FDA abuse-deterrent labeling in 2016—to reduce manipulation risks while preserving analgesic effect. This ADF focus differentiates products in a crowded pain market increasingly driven by safety and prescriber\/payer demand for responsible opioid use. The strategy supports long-term brand durability amid intensifying regulatory scrutiny.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtended-release and immediate-release options\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollegium offers both extended-release and immediate-release pain therapies to address acute and chronic settings. This breadth improves treatment personalization and titration flexibility and enables switch and step-therapy pathways within the same brand family. With 20.4% of US adults reporting chronic pain (CDC), the ER+IR portfolio strengthens formulary positioning through more comprehensive pain coverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuprenorphine and non-traditional mechanisms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIncluding buprenorphine-based partial agonists adds analgesia with a differentiated safety profile, notably a ceiling effect on respiratory depression, expanding options for patients at higher overdose risk from full agonists. As of 2024 clinical guidance and payer formularies increasingly favor safer modalities, giving physicians alternatives aligned with best-practice opioid stewardship. This strengthens Collegium’s chronic pain portfolio breadth and prescriber value proposition.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCNS focus with rigorous risk management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollegium focuses on CNS-mediated pain with REMS-aligned prescribing and monitoring (opioid REMS established 2012) and product-level controls such as Xtampza ER labeling and abuse-deterrent formulation choices (Xtampza ER approved 2016) to mitigate risk. This approach reinforces trust with regulators, payers and health systems amid 2021 US drug overdose context (107,622 deaths). It supports responsible access while preserving clinical effectiveness.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eREMS-aligned prescribing\u003c\/li\u003e\n\u003cli\u003eAbuse-deterrent labeling\/formulation\u003c\/li\u003e\n\u003cli\u003eRegulatory and payer trust\u003c\/li\u003e\n\u003cli\u003eResponsible access + clinical efficacy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient support and adherence services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatient support and adherence services at Collegium—hub services, co-pay programs, and digital adherence tools—help patients initiate and remain on therapy, complementing clinical value with practical support; medication nonadherence costs the US health system an estimated $100–300 billion annually, and these programs reduce abandonment from cost, access, or complexity while creating feedback loops for continuous improvement.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHub services: centralized access\/navigation\u003c\/li\u003e\n\u003cli\u003eCo-pay programs: lower financial barriers\u003c\/li\u003e\n\u003cli\u003eAdherence tools: reminders, monitoring\u003c\/li\u003e\n\u003cli\u003eFeedback loops: real-world outcomes inform optimization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAbuse-deterrent opioids, ER+IR and buprenorphine balance analgesia and safety\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium prioritizes abuse-deterrent opioids (Xtampza ER, ADF labeling 2016) and ER+IR plus buprenorphine options to balance analgesia and safety, supporting formulary access as prescribers\/payers favor safer modalities. REMS alignment and hub\/co-pay\/adherence programs reduce access friction amid high nonadherence costs and overdose risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eSource\/Year\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eChronic pain prevalence\u003c\/td\u003e\n\u003ctd\u003e20.4%\u003c\/td\u003e\n\u003ctd\u003eCDC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS OD deaths\u003c\/td\u003e\n\u003ctd\u003e107,622\u003c\/td\u003e\n\u003ctd\u003e2021\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNonadherence cost\u003c\/td\u003e\n\u003ctd\u003e$100–300B\u003c\/td\u003e\n\u003ctd\u003eEst.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Collegium Pharmaceutical’s Product, Price, Place, and Promotion strategies, using real brand practices and competitive context to ground recommendations. Ideal for managers, consultants, and marketers seeking a structured, ready-to-use analysis for reports, benchmarking, or strategy workshops.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Collegium Pharmaceutical’s 4P marketing mix into a concise, leadership-ready snapshot that clarifies product positioning, pricing, promotion, and placement to quickly relieve strategic ambiguity and align cross-functional teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale and specialty distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProducts flow through the three national wholesalers and a network of specialty pharmacies to maximize reach across retail, mail-order and specialty settings. This channeling supports controlled-substance handling and DEA-compliant distribution, helping stabilize supply to pharmacies and IDNs with predictable inventory cadence. Collegium reported approximately $342 million in net product sales in FY2024, reflecting broad channel coverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital and pain clinic access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollegium prioritizes distribution to sites where pain decisions occur, targeting over 6,090 US acute care hospitals (AHA 2023) and outpatient pain clinics to influence initiation and transitions of therapy. Hospital formularies and clinic access improve continuity from acute to chronic pain management and facilitate perioperative and step-down use cases. This site-focused approach supports seamless care pathways and formulary-driven adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer-aligned coverage pathways\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePayer-aligned coverage pathways coordinate prior authorization and step edits with payer networks, reducing denials in PBM-managed channels that cover about 80% of U.S. prescriptions. Aligning distribution to covered pharmacies cuts point-of-fill friction, improving on-formulary uptake among the ~50 million Medicare Part D beneficiaries. This supports tiered access and rebate-anchored networks, driving higher on-formulary fills and adherence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompliance with controlled-substance logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eScheduling across DEA Schedules I–V and PDMPs in all 50 states plus DC dictate Collegium’s shipping, storage, and dispensing controls; secure, trackable distribution and serialization reduce diversion and support compliance; standardized ordering and verification workflows minimize dispensing errors and protect patients while preserving channel integrity.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDEA Schedules I–V govern handling\u003c\/li\u003e\n\u003cli\u003ePDMPs: 50 states + DC\u003c\/li\u003e\n\u003cli\u003eTrackable distribution prevents diversion\u003c\/li\u003e\n\u003cli\u003eStandardized ordering reduces errors\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital prescribing and eVoucher enablement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDigital prescribing and electronic benefit verification (Surescripts 2024: \u0026gt;90% e-prescribing adoption) streamline access for Collegium; eVouchers and real-time benefit tools cut first-fill abandonment by an estimated 10–20% and lower patient cost surprises. Seamless integration with pharmacy workflows via payer and pharmacy connectors improves speed-to-therapy and persistence for specialty analgesics.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ee-prescribing: \u0026gt;90% adoption (Surescripts 2024)\u003c\/li\u003e\n\u003cli\u003eFirst-fill reduction: ~10–20%\u003c\/li\u003e\n\u003cli\u003eReal-time benefit tools: fewer cost surprises\u003c\/li\u003e\n\u003cli\u003eOutcome: faster initiation, higher persistence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eControlled-substance reach: \u003cstrong\u003e$342M\u003c\/strong\u003e, \u0026gt;90% e-prescribing, ~80% PBM\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium uses three national wholesalers plus specialty pharmacies to reach retail, mail-order and specialty channels, supporting DEA\/PDMP-compliant controlled-substance distribution; FY2024 net product sales ~$342M. Targeting 6,090 US acute hospitals and payer-aligned PBM channels (~80% coverage) improves on-formulary access; e-prescribing \u0026gt;90% (Surescripts 2024) speeds initiation.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 Sales\u003c\/td\u003e\n\u003ctd\u003e$342M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals targeted\u003c\/td\u003e\n\u003ctd\u003e6,090 (AHA 2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBM coverage\u003c\/td\u003e\n\u003ctd\u003e~80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ee-prescribing\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90% (Surescripts 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eCollegium Pharmaceutical 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Collegium Pharmaceutical 4P's Marketing Mix Analysis you’ll receive instantly after purchase—no surprises. It delivers a complete, editable review of Product, Price, Place and Promotion, fully formatted and ready for strategy or presentations. Buy with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56164998644089,"sku":"collegiumpharma-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/collegiumpharma-marketing-mix.png?v=1762744047","url":"https:\/\/portersfiveforce.com\/products\/collegiumpharma-marketing-mix","provider":"Porter's Five Forces","version":"1.0","type":"link"}